Salt, water and nephron: Mechanisms of action and link to hypertension and chronic kidney disease

Q Qian - Nephrology, 2018 - Wiley Online Library
Our knowledge on sodium and water homeostasis and regulation continues to evolve. A
considerable amount of new information in this area has emerged in recent years. This …

[HTML][HTML] Vasopressin–aquaporin-2 pathway: recent advances in understanding water balance disorders

M Ranieri, A Di Mise, G Tamma, G Valenti - F1000Research, 2019 - ncbi.nlm.nih.gov
The alteration of water balance and related disorders has emerged as being strictly linked to
the state of activation of the vasopressin–aquaporin-2 (vasopressin–AQP2) pathway. The …

Metabolomic analysis of urine samples by UHPLC-QTOF-MS: Impact of normalization strategies

Y Gagnebin, D Tonoli, P Lescuyer, B Ponte… - Analytica chimica …, 2017 - Elsevier
Among the various biological matrices used in metabolomics, urine is a biofluid of major
interest because of its non-invasive collection and its availability in large quantities …

Associations of urinary uromodulin with clinical characteristics and markers of tubular function in the general population

M Pruijm, B Ponte, D Ackermann… - Clinical journal of the …, 2016 - journals.lww.com
Results In both studies, positive associations were found between uromodulin and urinary
sodium, chloride, and potassium excretion and osmolality. In SKIPOGH, 24-hour uromodulin …

Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3: 4 trial

O Devuyst, AB Chapman, RT Gansevoort… - Journal of the …, 2017 - journals.lww.com
The vasopressin–cAMP–osmolality axis is abnormal in autosomal dominant polycystic
kidney disease (ADPKD). In the Tolvaptan Efficacy and Safety in Management of Autosomal …

[HTML][HTML] Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

RT Gansevoort, MDA van Gastel, AB Chapman… - Kidney international, 2019 - Elsevier
In the TEMPO 3: 4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist,
slowed the increase in total kidney volume and decline in estimated glomerular filtration rate …

Effect of increased water intake on plasma copeptin in healthy adults

G Lemetais, O Melander, M Vecchio, JH Bottin… - European journal of …, 2018 - Springer
Purpose Inter-individual variation in median plasma copeptin is associated with incident
type 2 diabetes mellitus, progression of chronic kidney disease, and cardiovascular events …

Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes

G Velho, R El Boustany, G Lefèvre… - Diabetes …, 2016 - Am Diabetes Assoc
OBJECTIVE Plasma copeptin, a surrogate for vasopressin, has been associated with a
decline in renal function and albuminuria in population-based studies as well as with …

Antidiuretic hormone and serum osmolarity physiology and related outcomes: what is old, what is new, and what is unknown?

M Kanbay, S Yilmaz, N Dincer, A Ortiz… - The Journal of …, 2019 - academic.oup.com
Context Although the physiology of sodium, water, and arginine vasopressin (AVP), also
known as antidiuretic hormone, has long been known, accumulating data suggest that this …

Renocardiovascular biomarkers: from the perspective of managing chronic kidney disease and cardiovascular disease

S Niizuma, Y Iwanaga, T Yahata… - Frontiers in cardiovascular …, 2017 - frontiersin.org
Mortality among the patients with chronic kidney disease (CKD) and end-stage renal
disease (ESRD) remains high because of the very high incidence of cardiovascular disease …